Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal

Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal

Submitted by admin on February 20, 2019 - 10:00am
Source: 
Endpoints
News Tags: 
Xencor
XmAb14045
bispecific antibodies
acute myeloid leukemia
Headline: 
Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal
snippet: 

Researchers at Xencor have slammed the brakes on recruiting more patients for an early-stage study of XmAb14045, a CD123 x CD3 bispecific antibody in the race for acute myeloid leukemia. 

Do Not Allow Advertisers to Use My Personal information